Table 1 Patient characteristics.
Acute lymphoblastic leukemia (n = 31) | Non-Hodgkin lymphoma (n = 23) | |
|---|---|---|
Age, median (range), years | 10 (1–20) | 60 (33–76) |
Gender, n (%) | ||
Female | 9 (29) | 8 (35) |
Male | 22 (71) | 15 (65) |
Lymphoma subtype, n (%) | ||
Diffuse large B cell lymphoma | — | 9 (39) |
Primary mediastinal B cell lymphoma | — | 1 (4) |
Transformed indolent lymphoma | — | 3 (13) |
Follicular lymphoma | — | 3 (13) |
Mantle cell lymphoma | — | 6 (26) |
Burkitt lymphoma | — | 1 (4) |
Primary indication, n (%) | ||
Primary indication | 3 (10) | — |
Refractory relapse | 28 (90) | 21 (91) |
Non-refractory relapse | — | 2 (9) |
Previous systemic therapies, median (range) | 3 (1–4) | 5 (2–7) |
Previous therapy, n (%) | ||
Autologous HSCT | — | 10 (44) |
Allogeneic HSCT | 13 (42) | — |
Blinatumomab | 11 (35) | — |
Anthracycline-containing regimen | — | 22 (96) |
Rituximab | 23 (100) | |
Bone marrow leukemia burden, n (%) | ||
<5% | 13 (42) | — |
5–20% | 5 (16) | — |
>20% | 13 (42) | — |
Bone marrow blast, median, % (range) | 9 (0–99) | — |
Bone marrow CD19 expression of gated leukemia population, median % (range) | 98 (35–100) | — |
Bulky lymphoma (i.e. >7.5 cm longest diameter) | — | 6 (26) |
Elevated LDH prior to conditioning chemotherapy | — | 8 (35) |
